E
Telo Genomics Corp.
TDSGF
$0.0882
$0.020630.47%
E
Sell
8/11/2023Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 8/11/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.03 to 0.05, and the quick ratio declined from 14.33 to 6.17.
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 8/11/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.03 to 0.05, and the quick ratio declined from 14.33 to 6.17.
D
Sell
3/14/2023Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 0.02 to 0.03, and operating cash flow declined 36.12% from -$410 to -$558.1.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 0.02 to 0.03, and operating cash flow declined 36.12% from -$410 to -$558.1.
D
Sell
2/23/2023Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 02/23/2023.
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 14.37 to 12.9.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 14.37 to 12.9.
D
Sell
5/5/2022Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and valuation index.
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and valuation index.
D
Sell
4/20/2022Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index and total return index. Operating cash flow declined 79.25% from -$257.8 to -$462.1.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index and total return index. Operating cash flow declined 79.25% from -$257.8 to -$462.1.
D
Sell
11/9/2021Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from E+ on 11/09/2021.
Telo Genomics Corp. (TDSGF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/28/2020Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 5/28/2020 due to an increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.0175 to -$0.0058, EBIT increased 43.73% from -$425.1 to -$239.2, and the quick ratio increased from 3.1 to 4.17.
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 5/28/2020 due to an increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.0175 to -$0.0058, EBIT increased 43.73% from -$425.1 to -$239.2, and the quick ratio increased from 3.1 to 4.17.
D
Sell
5/19/2020Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 5/19/2020 due to a decline in the volatility index.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 5/19/2020 due to a decline in the volatility index.
D
Sell
5/1/2020Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from E+ on 5/1/2020 due to an increase in the volatility index and total return index.
Telo Genomics Corp. (TDSGF) was upgraded to D from E+ on 5/1/2020 due to an increase in the volatility index and total return index.
E
Sell
4/28/2020Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 4/28/2020 due to a decline in the solvency index, valuation index and volatility index.
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 4/28/2020 due to a decline in the solvency index, valuation index and volatility index.
D
Sell
3/31/2020Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D- from E+ on 3/31/2020 due to an increase in the valuation index.
Telo Genomics Corp. (TDSGF) was upgraded to D- from E+ on 3/31/2020 due to an increase in the valuation index.
E
Sell
3/16/2020Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 3/16/2020 due to a decline in the valuation index.
Telo Genomics Corp. (TDSGF) was downgraded to E+ from D- on 3/16/2020 due to a decline in the valuation index.
D
Sell
3/4/2020Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 3/4/2020 due to a noticeable decline in the efficiency index and growth index. Net income declined 304.86% from -$105 to -$425.1, EBIT declined 304.86% from -$105 to -$425.1, and earnings per share declined from -$0.0079 to -$0.0227.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 3/4/2020 due to a noticeable decline in the efficiency index and growth index. Net income declined 304.86% from -$105 to -$425.1, EBIT declined 304.86% from -$105 to -$425.1, and earnings per share declined from -$0.0079 to -$0.0227.
D
Sell
11/29/2019Upgraded
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 11/29/2019 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0115 to -$0.0079, and EBIT increased 23.58% from -$137.4 to -$105.
Telo Genomics Corp. (TDSGF) was upgraded to D from D- on 11/29/2019 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0115 to -$0.0079, and EBIT increased 23.58% from -$137.4 to -$105.
D
Sell
10/30/2019Downgrade
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 10/30/2019 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0013 to -$0.0051, net income declined 77.47% from -$86.1 to -$152.8, and operating cash flow declined 70.22% from -$46 to -$78.3.
Telo Genomics Corp. (TDSGF) was downgraded to D- from D on 10/30/2019 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0013 to -$0.0051, net income declined 77.47% from -$86.1 to -$152.8, and operating cash flow declined 70.22% from -$46 to -$78.3.
D
Sell
11/19/2018Upgraded
3D Signatures Inc. (TDSGF) was upgraded to D from D- on 11/19/2018 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 51.52% from -$780.7 to -$378.5.
3D Signatures Inc. (TDSGF) was upgraded to D from D- on 11/19/2018 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 51.52% from -$780.7 to -$378.5.
D
Sell
6/5/2018Upgraded
3D Signatures Inc. (TDSGF) was upgraded to D- from E+ on 6/5/2018 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0236 to -$0.0114, and EBIT increased 39.89% from -$1.19M to -$716.9.
3D Signatures Inc. (TDSGF) was upgraded to D- from E+ on 6/5/2018 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0236 to -$0.0114, and EBIT increased 39.89% from -$1.19M to -$716.9.
E
Sell
9/21/2017Downgrade
3D Signatures Inc. (TDSGF) was downgraded to E+ from D- on 9/21/2017 due to a decline in the volatility index and total return index.
3D Signatures Inc. (TDSGF) was downgraded to E+ from D- on 9/21/2017 due to a decline in the volatility index and total return index.
D
Sell
8/1/2017Upgraded
3D Signatures Inc. (TDSGF) was upgraded to D- from E on 8/1/2017 due to an increase in the efficiency index and valuation index.
3D Signatures Inc. (TDSGF) was upgraded to D- from E on 8/1/2017 due to an increase in the efficiency index and valuation index.
E
Sell
5/1/2017Upgraded
3D Signatures Inc. (TDSGF) was upgraded to E from E- on 5/1/2017 due to an increase in the valuation index.
3D Signatures Inc. (TDSGF) was upgraded to E from E- on 5/1/2017 due to an increase in the valuation index.
E
Sell
3/3/2017Downgrade
3D Signatures Inc. (TDSGF) was downgraded to E- from E on 3/3/2017 due to a noticeable decline in the volatility index.
3D Signatures Inc. (TDSGF) was downgraded to E- from E on 3/3/2017 due to a noticeable decline in the volatility index.
E
Sell
2/16/2017Upgraded
3D Signatures Inc. (TDSGF) was upgraded to E from E- on 2/16/2017 due to an increase in the total return index and volatility index.
3D Signatures Inc. (TDSGF) was upgraded to E from E- on 2/16/2017 due to an increase in the total return index and volatility index.
E
Sell
2/6/2017None
Telo Genomics Corp. (TDSGF) was downgraded to E- from U on 02/06/2017.
Telo Genomics Corp. (TDSGF) was downgraded to E- from U on 02/06/2017.
OTC PK
03/14/2025 9:43AM Eastern
Quotes delayed
